Plus Therapeutics, Inc. (PSTV)

Market Cap	45.29M +331.3%
Revenue (ttm)	5.18M -0.5%
Net Income	-11.93M
EPS	-2.62
Shares Out	6.86M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	103,460
Open	6.80
Previous Close	6.59
Day's Range	6.56 - 7.14
52-Week Range	2.90 - 23.43
Beta	1.40
Analysts	Strong Buy
Price Target	38.00 (+475.76%)
Earnings Date	May 15, 2026

About PSTV

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company’s lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat various solid organ cancers, such as primary and sec...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1996
• Employees: 28
• Stock Exchange: NASDAQ
• Ticker Symbol: PSTV
• Website: https://plustherapeutics.com

Financial Performance

In 2025, Plus Therapeutics's revenue was $5.21 million, a decrease of -10.49% compared to the previous year's $5.82 million. Losses were -$22.39 million, 72.5% more than in 2024.

Analyst Summary

According to 4 analysts, the average rating for PSTV stock is "Strong Buy." The 12-month stock price target is $38.0, which is an increase of 475.76% from the latest price.

Price Target

$38.0

(475.76% upside)

Analyst Consensus: Strong Buy